Evaxion Biotech A/S

Equities

EVAX

US29970R2040

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 03:14:44 2024-05-28 pm EDT			5-day change	1st Jan Change
3.905 ^USD	-3.34%		+9.38%	-43.05%

02:35pm	Earnings Flash (EVAX) EVAXION BIOTECH Reports Q1 Revenue $51,000	MT
02:21pm	Evaxion Biotech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

BioStock: Can AI help solve cancer? - Evaxion Biotech talks AI, cancer and partnerships

December 22, 2023 at 02:33 am EST

At the end of August, Evaxion Biotech announced a change in top management, hiring Christian Kanstrup as CEO. Kanstrup stopped by the BioStock Studio to tell us about his vision for Evaxion and how he plans to implement that vision.

Watch the interview with Christian Kanstrup at biostock.se:

Can AI help solve cancer? - Evaxion Biotech talks AI, cancer and partnerships - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/evaxion-biotech/r/biostock--can-ai-help-solve-cancer----evaxion-biotech-talks-ai--cancer-and-partnerships,c3898367

Latest news about Evaxion Biotech A/S

Earnings Flash (EVAX) EVAXION BIOTECH Reports Q1 Revenue $51,000	08:35am	MT
Evaxion Biotech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	08:21am	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower	May. 24	MT
Evaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination Treatment	May. 24	MT
Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024	May. 23	CI
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	May. 23	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	May. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	May. 21	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	May. 15	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	May. 13	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	May. 06	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	May. 03	MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	May. 02	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	May. 01	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	Apr. 29	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
Evaxion Biotech A/S Elects Lars Staal Wegner as A New Board Member	Apr. 25	CI
Evaxion Announces Phase 2 Clinical Trial Update	Apr. 17	CI
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	Apr. 11	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 08	MT
Certain Warrants of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
Certain American Depositary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
Certain Ordinary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT

Chart Evaxion Biotech A/S

Duration

Period

More charts

Company Profile

Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Nordic Digital Science & Innovation Day

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.04 USD

Average target price

11.75 USD

Spread / Average Target

+190.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVAXION BIOTECH A/S	-43.05%	21.86M
MODERNA, INC.	+53.02%	63.85B
IQVIA HOLDINGS INC.	-2.35%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.45%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.50%	18.69B
BIO-TECHNE CORPORATION	+2.71%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.24%	12.11B
MEDPACE HOLDINGS, INC.	+27.75%	12.07B

Other Biotechnology & Medical Research